Croatia’s Prime Minister, Andrej Plenković, visited JGL today. Together with a delegation of the Government of the Republic of Croatia, the Prime Minister attended a meeting with the representatives of the company’s Management Board, where the company presented the new investment project Integra 2020, which is of strategic importance for its further business development.
“The Integra 2020 project is a new investment and development project for JGL in which we plan to invest HRK 373 million in sterile pharmaceutical production, research and development, a new pilot plant and a robotic logistics and distribution centre. The project envisages a 60 percent increase in sterile production capacity in order to continue to meet demand, as well as an integration of the processes of research and development, production and quality in a single location, which will significantly improve the development and technological competence of the company and its global competitiveness,” says Mislav Vučić, JGL’s Chief Executive Officer.
As part of the visit, the delegation, led by the Prime Minister, was given a tour of the technologically advanced production facilities of sterile pharmaceutical forms within the JGL Pharma Valley complex, as well as the construction site of future sterile production within the Integra 2020 project.
“I would like to congratulate JGL on its successful business operations and excellent financial results, and especially on the positioning of its key brand Aqua Maris, which holds an eight percent share of the global market. I especially welcome the new investment within Integra 2020, a project that will integrate a number of production and research and development activities of the company and its partners. JGL is a company that has the capacity to go a step further, which creates new values and is able to develop and produce products that generate revenue, profit and conquer global markets in challenging market conditions,” says Prime Minister Andrej Plenković, concluding that through its business concept of automation and robotics, JGL is already actively living the fourth industrial revolution.
“Integra 2020 brings significant investments in the development of high-tech industry and state-of-the-art digital technologies, which will raise both Croatian and European pharmaceutical standards. The project also embodies a new, development dimension of JGL’s future on its path of stable and sustainable growth, while at the same time having a significant impact on the development of the Croatian pharmaceutical industry, and the EU pharmaceutical sector, as one of the key strategic plans for European industry,” concludes Ivo Usmiani, President of JGL’s Board.